Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 29, 2014 (13 years ago)

Oxcarbazepine Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Tablet Specifications: Broken Tablets Present.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Oxcarbazepine Tablets, 300 mg, 100 tablet bottles, Rx Only. Distributed by: Caraco Pharmaceutical Laboratories, Ltd., 1150 Elijiah McCoy Drive, Detroit, MI, 48202. Manufactured by: Sun Pharmaceutical Ind. Ltd., Acme Plaza, Andheri-Kurla Road, Andheri (East), Mumbai-400 059, India. NDC 62756-184-88, Rx only, 100 Tablets; Pharmacist: Dispense the Medication Guide provided separately to each patient. Each film-coated tablet contains 300 mg oxcarbazepine, USP, Usual Dosage: See package insert, Dispense in tight container (USP) tore at 25 C (77 F) excursions permitted.... Distributed by Caraco Pharmaceuticals Detroit, MI....

Affected NDC 62756-0184-88

Compare with the code on your package — it is the most precise check available.

Drug: Oxcarbazepine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Oxcarbazepine
NDC 62756-0184
300 mg/1 Tablet, Film Coated
Oral
Sun Pharmaceutical Industries, Inc. Rx
Recalling firm
Caraco Pharmaceutical Laboratories Ltd.
NDC code
62756-184-88
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1081-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Oxcarbazepine recalls

See all
Class II · Moderate risk

Oxcarbazepine active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-828-2015
Class I · High risk

Oxcarbazepine Tablets

Labeling: Label Mix-Up: Some cartons of AHP Ibuprofen Tablets, USP, 600mg, lot #142588 that contain blister cards filled with Ibuprofen tablets, 600mg drug product, were found to be mis-labeled with blister card print identifying the product as AHP Oxcarbazepine Tablets, 300mg, lot #142544.

Terminated Labeling / mix-up American Health Packaging NDC 62584-143-01 D-1590-2014

Other recalls by Caraco Pharmaceutical Laboratories Ltd.

All 2014 recalls
Class II · Moderate risk

Cephalexin Capsules

CGMP Deviations: These products are being recalled because they were manufactured with active pharmaceutical ingredients (APIs) that were not manufactured with good manufacturing practices.

Terminated cGMP deviation Caraco Pharmaceutical Laboratories, Ltd. NDC 62756-294-88 D-1511-2014
Class II · Moderate risk

Cephalexin Capsules

CGMP Deviations: These products are being recalled because they were manufactured with active pharmaceutical ingredients (APIs) that were not manufactured with good manufacturing practices.

Terminated cGMP deviation Caraco Pharmaceutical Laboratories, Ltd. NDC 62756-293-88 D-1510-2014
Class II · Moderate risk

Gemcitabine For Injection USP

Lack of Assurance of Sterility: A particle excursion for a different batch of the same product may lead to a lack of sterility assurance.

Terminated Sterility / contamination Caraco Pharmaceutical Laboratories, Ltd. NDC 47335-154-40 D-1407-2014